Topic:
M&A
Latest Headlines
Latest Headlines
HemCon, a struggling wound dressing device maker, is sold
A year after HemCon Medical Technologies filed for Chapter 11 reorganization following the loss of a patent fight, the Oregon maker of gels and dressings has been sold.
Theragenics weighs buyout offer worth up to $71.4M
As its net profits careen into the red, Theragenics is considering a buyout offer worth up to $71.4 million from private equity outfit Juniper.
Actavis, Warner in buyout talks potentially worth $5B-plus
While Valeant Pharmaceuticals was chatting up Actavis about a potential merger-of-equals, Actavis was apparently mulling a bid for Warner Chilcott, the Irish drugmaker that specializes in women's health and dermatology.
IT outfit Instem acquires Logos to penetrate early clinical trials market
Instem has bought a ticket to play a larger role in the market for early-stage clinical trials. The provider of IT solutions has acquired Logos Technologies, which provides electronic data-capture (EDC) software for pharma, biotech and CRO companies.
Biosensors International grabs next-gen imaging company for $51M
Swiss cardiac stent maker Biosensors International will pay at least $51 million for U.S.-based Spectrum Dynamics, a developer of high-definition medical imaging technology.
AbbVie, Pfizer's Zoetis deals ignite enormous leap in M&A value
Pfizer's spinoff of its animal health business into Zoetis is the biggest IPO this year. And the spinoff that created the newest Big Pharma company, AbbVie, was no slouch.
Amgen forges Chinese JV for Vectibix
The China drug market is getting trickier but that is not stopping the big names of biotech and pharma from plowing ahead with tie-ups of various kinds to sell into the enormous market. Amgen today said it is ready to attack the Chinese market with one of its cancer drugs.
Sony sinks $10M into Israeli medical device incubator
As Sony works to build its presence in the medical device world, the Japanese giant is investing $10 million in Rainbow Medical, an Israeli incubator with portfolio companies that make stents, stimulators and other devices.
Report: ICU weighing billion-dollar sale
ICU Medical is considering selling itself, retaining advisers to find suitors and weigh offers that may soar past $1 billion.
UPDATED: Takeda beefs up new vaccines arm with $250M bolt-on buyout of Inviragen
A couple of months after moving its experimental dengue vaccine into the second phase of a mid-stage study, Fort Collins, CO-based Inviragen has been snapped up by Takeda in a $250 million deal.
